CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	True Up Costs December 2020	Avitide, Inc.	ARTeSYN Biosolutions Holdings Ireland Limited	Common Stock	Common Stock Avitide, Inc.	Common Stock ARTeSYN Biosolutions Holdings Ireland Limited	Additional Paid-in Capital	Additional Paid-in Capital True Up Costs December 2020	Additional Paid-in Capital Avitide, Inc.	Additional Paid-in Capital ARTeSYN Biosolutions Holdings Ireland Limited	Accumulated Other Comprehensive Income (Loss)	Accumulated Earnings/(Deficit)
Balance at Dec. 31, 2019	$ 1,059,768				$ 521			$ 1,068,431				$ (15,027)	$ 5,843
Balance (in shares) at Dec. 31, 2019					52,078,258
Net income	59,926												59,926
Exercise of stock options and vesting of stock units	8,140				$ 6			8,134
Exercise of stock options and vesting of stock units (in shares)					584,589
Issuance of commons stock pursuant to the acquisition				$ 69,422			$ 4				$ 69,418
Issuance of commons stock pursuant to the acquisition, (in shares)							372,990
Proceeds from issuance of common stock, net of issuance costs	297,775				$ 17			297,758
Proceeds from issuance of common stock, net of issuance costs (in shares)					1,725,000
Stock-based compensation expense	17,007							17,007
Balance at Dec. 31, 2020	1,529,150				$ 548			1,460,748				2,085	65,769
Balance (in shares) at Dec. 31, 2020					54,760,837
Translation adjustment	17,112											17,112
Net income	128,291												128,291
Exercise of stock options and vesting of stock units	3,879				$ 3			3,876
Exercise of stock options and vesting of stock units (in shares)					300,721
Issuance of commons stock pursuant to the acquisition		$ 145	$ 82,968			$ 2			$ 145	$ 82,966
Issuance of commons stock pursuant to the acquisition, (in shares)						271,096
Stock-based compensation expense	27,500							27,500
Issuance of common stock for debt conversion	2				$ 0			2
Issuance of common stock for debt conversion (in shares)					7
Tax withholding on vesting of restricted stock	(2,897)				$ 0			(2,897)
Tax withholding on vesting of restricted stock (in shares)					(11,204)
Balance at Dec. 31, 2021	1,750,067				$ 553			1,572,340				(16,886)	194,060
Balance (in shares) at Dec. 31, 2021					55,321,457
Translation adjustment	(18,971)											(18,971)
Net income	185,959												185,959
Exercise of stock options and vesting of stock units	3,707				$ 3			3,704
Exercise of stock options and vesting of stock units (in shares)					326,192
Stock-based compensation expense	27,316							27,316
Issuance of common stock for debt conversion	(6)				$ 1			(7)
Issuance of common stock for debt conversion (in shares)					21
Tax withholding on vesting of restricted stock	(17,018)				$ (1)			(17,017)
Tax withholding on vesting of restricted stock (in shares)					(89,972)
Balance at Dec. 31, 2022	1,910,700				$ 556			1,547,266				(34,394)	397,272
Balance (Accounting Standards Update 2020-06) at Dec. 31, 2022	(21,817)							$ (39,070)					$ 17,253
Balance (in shares) at Dec. 31, 2022					55,557,698
Translation adjustment	$ (17,508)											$ (17,508)